×

Message

Sorry - this event cannot be viewed using the link provided. Its possible the item may have been updated while you have been viewing the webpage.

wuxi-apptec-logo

Chinese CRO WuXi AppTec has opened a biologics manufacturing plant in Shanghai that will initially serve a joint venture it has with AstraZeneca ($AZN) to develop an IL-6 inhibitor to treat rheumatoid arthritis and autoimmune disorders that is being developed for the Chinese market.

While providing few details of the new facility, the company claims that it is the first biologics plant in China to meet GMP standards for the U.S. and EU as well as China, and is the first biologics plant in the world to use all disposable technology.